How volatile is REGN?

Over the past year, REGN had an annualised volatility of 32.77%, based on daily closes. Its deepest fall from a high in that time was 26.05%, from January 7, 2026 to June 1, 2026. Its beta against the S&P 500 was 0.51.

What was the biggest price drop for REGN?

The deepest fall in our weekly price history since October 2006 was 59.11%, from a high in the week of August 19, 2024 to a low in the week of May 26, 2025. The price has not yet returned to that high.

Which month has historically been best for REGN?

Since 2015, July has had the highest average return for REGN (+6.28%, up in 10 of 12 years) and September the lowest (-4.22%, up in 1 of 12 years). Past seasonal patterns do not predict future returns.

stock · yahoo

REGN

$790.74

▼ 5.6 (-0.7%)

Last close · Oct 16

Below: live stock price for REGN (REGN), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

REGN (REGN) is a Healthcare company based in United States. Operating in Biotechnology, it employs about 15,410 people. Over the past year REGN traded between 572.75 and 859.34 USD. It currently yields 0.48% in dividends.

Day

-0.70%

-5.60

Week

+5.92%

+44.20

Month

+0.75%

+5.89

Year

—

Prev close: $796.34
Volume (24h): —
Market cap: —
Currency: USD

Score

65/ 100 · Solid

Coverage: 7/7

Value66
Quality65
Momentum58
Growth39
Risk77
Dividend53
Liquidity100

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

SidewaysFit 0%Pace +0.02% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 791.2871
+20 bars: 792.0427
+60 bars: 792.3351
+120 bars: 792.3459

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0546 USD.

Interpretation

Composite signals look solid. Strength: balance-sheet liquidity with weakness: growth. Price sits in the middle of the recent range, trend is roughly flat.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
66/100
Value looks solid — driven by P/E (19.55).
P/E:19.55P/B:2.5PEG:1.35
Quality
65/100
Quality looks solid — driven by Gross margin (44.46%).
ROE:14.04%ROA:6.53%Profit margin:27.87%Gross margin:44.46%
Momentum
58/100
Momentum looks mixed — driven by 52w change (37.10%).
52w change:37.10%
Growth
39/100
Growth looks weak — driven by Revenue growth (16.70%).
Revenue growth:16.70%Earnings growth:-4.50%
Risk
77/100
Risk looks strong — driven by Debt / equity (8.54).
Beta:0.15Debt / equity:8.54Short interest:2.21%
Dividend
53/100
Dividend looks mixed — driven by Payout ratio (9.00%).
Dividend yield:0.48%Payout ratio:9.00%
Liquidity
100/100
Liquidity looks strong — driven by Current ratio (3.34).
Current ratio:3.34Quick ratio:2.63

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 250 days.

Position in range76%

572.75 low859.34 high

Where the price sits between the window low and high.

Volatility (annualised): 32.8%
Max drawdown: -26.1%
Below period high: -8.0%
Best day: +11.82%
Worst day: -9.82%
Up days: 50%
Current streak: 1 down
Typical day swing: 2.6%
Volume vs average: -20%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

810.8916 USD+2.55%

Fib 23.6% retracement

Next level below

780.9192 USD-1.24%

Fib 38.2% retracement

Levels derived from: 859.34 high → 654.05 low · 60 bars

Resistance
Fib +161.8% extension
not reached
1,191.5 USD
+50.68% from current
Resistance
Fib +100% extension
not reached
1,064.63 USD
+34.64% from current
Resistance
Fib +61.8% extension
not reached
986.2093 USD
+24.72% from current
Resistance
Fib +27.2% extension
not reached
915.1789 USD
+15.74% from current
Resistance
Fib 23.6% retracement
tested 9×
810.8916 USD
+2.55% from current
Current
790.74 USD
Support
Fib 38.2% retracementNearest
tested 13×
780.9192 USD
-1.24% from current
Support
Fib 50% midpoint
tested 9×
756.695 USD
-4.31% from current
Support
Fib 61.8% retracement
tested 7×
732.4708 USD
-7.37% from current
Support
Fib 78.6% retracement
tested 2×
697.9821 USD
-11.73% from current
Support
Fib −27.2% extension
not reached
598.2111 USD
-24.35% from current
Support
Fib −61.8% extension
not reached
527.1807 USD
-33.33% from current
Support
Fib −100% extension
not reached
448.7599 USD
-43.25% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $859.34
52w low: $572.75
52w change: 37.10%
Day high: $805.68
Day low: $787.33
P/E (TTM): 19.55
Forward P/E: 12.77
PEG: 1.35
Price / Book: 2.5
Beta (5Y): 0.15
Enterprise value: 73.67B
EV / Revenue: 4.74
EV / EBITDA: 15.67
EPS (TTM): $40.44
Forward EPS: $61.94
Dividend yield: 0.48%
Dividend rate: $3.76
Payout ratio: 9.00%
Revenue (TTM): 15.53B
EBITDA: 4.7B
Free cash flow: 3.07B
Total cash: 7.99B
Total debt: 2.71B
Debt / Equity: 8.54
Current ratio: 3.34
Quick ratio: 2.63
Profit margin: 27.87%
Gross margin: 44.46%
Return on assets: 6.53%
Return on equity: 14.04%
Shares outstanding: 101.14M
Float: 95.85M

Sector: HealthcareIndustry: BiotechnologyHQ: United StatesEmployees: 15.41Kwww.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Analyst & Risk

Consensus

Buy

Mean rating1.82 / 5

Analysts27

Next earnings2026-10-30

Strong buy 4Buy 15Hold 8Strong sell 1

Analyst price target

$863.93

Mean target · 27 analysts

+9.3%

upside

Low $730.00Now $790.74High $1,030.00

Beta (vs S&P 500): 0.15; very stable
52-week change: 37.10%
Short % of float: 2.21%
Short ratio (days): 2.91
Debt / Equity: 8.54; very high leverage
Current ratio: 3.34
Quick ratio: 2.63
ROE: 14.04%
ROA: 6.53%
PEG ratio: 1.35; fair
EV / Revenue: 4.74
EV / EBITDA: 15.67
Revenue growth: 16.70%
Earnings growth: -4.50%
EBITDA: 4.7B
Free cash flow: 3.07B
Total cash: 7.99B
Total debt: 2.71B
Insider holdings: 2.08%
Institutional: 93.40%

Recent rating changes

2026-10-15UBSNeutral → Buyup
2026-10-08RBC CapitalSector Perform → Sector Performmain
2026-10-07Truist SecuritiesBuy → Buymain
2026-10-07Morgan StanleyEqual-Weight → Equal-Weightmain
2026-10-06JP MorganOverweight → Overweightmain
2026-10-01JefferiesBuy → Buymain
2026-10-01Argus ResearchHold → Buyup
2026-09-29RBC CapitalSector Perform → Sector Performreit

Financial documents

REGN performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$746.54	$746.54	+5.92%
1 month$774.61	$774.61	+2.08%
3 months$678.94	$678.94	+16.47%
6 months$746.00	$746.00	+6.00%
Year to date$771.87	$771.87	+2.44%
1 year$576.77	$576.77	+37.10%
3 years$839.63	$839.63	-5.82%	-1.97%
5 years$553.24	$553.24	+42.93%	+7.40%
10 years$371.68	$371.68	+112.7%	+7.84%
Since Oct 2006$19.66	$19.66	+3,922%	+20.32%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

REGN all-time high and low

Highest since Oct 2006

$1,211.20

week of Aug 26, 2024

34.71% below the high

Lowest since Oct 2006

$11.81

week of Mar 9, 2009

6,596% above the low

52-week range

76%

Low

$572.75

Oct 23, 2025

High

$859.34

Sep 3, 2026

The latest price sits at 76% of this range.

Highs and lows include intraday prices.

REGN risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 32.77%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -26.05%; Jan 7, 2026 → Jun 1, 2026 · Recovered on Aug 19, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Oct 2006): -59.11%; Aug 2024 → May 2025 · Not yet recovered.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.13; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): 0.51; On average, REGN moved 0.51% for each 1% move in the S&P 500 on the same day.

REGN drawdown from peak

How far the price stood below its previous high, based on weekly closes since Oct 2006.

REGN seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

REGN seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.9%	+5.4%	-1.2%	-8.5%	-13%	+1.4%	+22%	+4.8%	-5.1%	+4.3%*			+2.4%*
2025	-5.5%	+3.8%	-8.8%

REGN price history

Yearly open, high, low and close, newest first.

REGN price history
Year	Open	High	Low	Close	Change
2026YTD	$774.25	$859.34	$591.52	$790.74	+2.44%
2025	$708.04	$792.77	$476.49	$771.87	+8.35%
2024	$873.91	$1,211.20	$693.00	$712.40	-18.89%
2023	$721.86	$899.86	$668.00	$878.29	+21.73%
2022	$625.00	$779.00	$538.01	$721.49	+14.25%

Frequently asked questions about REGN

What is the price of REGN today?

As of October 16, 2026, the price of REGN is $790.74, down 0.70% from the previous close.

What is the all-time high of REGN?

The highest price for REGN in our data, which starts in October 2006, is $1,211.20, reached in the week of August 26, 2024. At $790.74, the latest price is 34.71% below it.

How much has REGN gained this year?

REGN is up 2.44% so far in 2026: it closed 2025 at $771.87 and is at $790.74 now.

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	-1.2%	+1.8%	+3.0%	-3.4%	+1.1%	+2.1%	+6.3%	+3.2%	-4.2%	-0.3%	+3.5%	-1.7%	+7.8%
Years up	42%	58%	67%	33%	58%	67%	83%	58%	8%	45%	64%	27%	73%

Year	Open	High	Low	Close	Change
2021	$486.85	$686.62	$441.00	$631.52	+30.72%
2020	$373.74	$664.64	$328.13	$483.11	+29.41%
2019	$364.73	$442.00	$271.37	$373.32	+2.95%
2018	$379.48	$416.49	$281.89	$362.62	-3.55%
2017	$370.84	$543.55	$340.09	$375.96	+2.42%
2016	$531.76	$532.91	$325.35	$367.09	-32.38%
2015	$412.82	$605.93	$393.00	$542.87	+31.29%
2014	$275.67	$437.64	$262.97	$413.48	+49.25%
2013	$167.02	$319.83	$154.16	$277.04	+64.93%
2012	$56.51	$188.95	$56.01	$167.97	+203.0%
2011	$32.69	$79.90	$32.32	$55.43	+68.84%
2010	$24.24	$33.94	$20.45	$32.83	+35.77%
2009	$17.10	$24.97	$11.81	$24.18	+32.64%
2008	$24.26	$25.25	$12.62	$18.23	-25.38%
2007	$19.93	$28.74	$13.55	$24.43	+21.72%
2006from October	$19.60	$24.85	$18.86	$20.07	—

Month	Close	Change
September 2026	$758.27	-5.11%
August 2026	$799.08	+4.78%
July 2026	$762.63	+22.31%
June 2026	$623.54	+1.42%
May 2026	$614.78	-13.05%
April 2026	$707.06	-8.49%

Month	Close	Change
March 2026	$772.64	-1.16%
February 2026	$781.67	+5.42%
January 2026	$741.45	-3.94%
December 2025	$771.87	-1.07%
November 2025	$780.19	+19.70%
October 2025	$651.80	+15.59%

REGN

Financials

Analyst & Risk

Recent rating changes

Financial documents

REGN performance

REGN all-time high and low

52-week range

REGN risk metrics

REGN drawdown from peak

REGN seasonality

REGN price history

Frequently asked questions about REGN

What is the price of REGN today?

What is the all-time high of REGN?

How much has REGN gained this year?

Recent news

Learn the terms

Live discussion

REGN performance

REGN all-time high and low

52-week range

REGN risk metrics

REGN drawdown from peak

REGN seasonality

REGN price history

Frequently asked questions about REGN

What is the price of REGN today?

What is the all-time high of REGN?

How much has REGN gained this year?

REGN month-end closes

How volatile is REGN?

What was the biggest price drop for REGN?

Which month has historically been best for REGN?